Telix Pharmaceuticals (ASX: TLX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Telix Pharmaceuticals Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Telix Pharmaceuticals (ASX: TLX)
Latest News
Broker Notes
Bell Potter says this growing ASX 200 stock can rise over 40%
Share Market News
5 things to watch on the ASX 200 on Friday
Share Gainers
Here are the top 10 ASX 200 shares today
Share Market News
Why Botanix, Dexus, Strickland, and Telix shares are charging higher today
Healthcare Shares
Telix shares jump 7% on big US news
Healthcare Shares
These 5 ASX 200 healthcare shares gained the most weight in FY25
Growth Shares
3 ASX growth shares to buy before the next bull market
Healthcare Shares
Top broker names the best ASX healthcare shares to buy in FY26
Healthcare Shares
Up 36% in a year, why this $8 billion ASX 200 stock has still a 'strong growth forecast'
How to invest
How to make $5,000 a month in passive income
Broker Notes
Bell Potter names the best ASX 200 shares to buy in FY26
Broker Notes
2 of the best ASX 200 shares that money can buy
Frequently Asked Questions
-
No, Telix does not pay dividends at this time.
-
Telix Pharmaceuticals Ltd listed on the ASX on 15 November 2017.
TLX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Telix Pharmaceuticals
Telix Pharmaceuticals Ltd (ASX: TLX) is a commercial-stage biopharmaceutical company focused on the ongoing development of diagnostic and therapeutic ('theranostic') products using targeted radiation. This process treats cancerous or diseased cells, an alternative approach to many cancer therapies which also attack healthy tissue at the same time.
Telix has received global regulatory approvals from the Australian Therapeutic Goods Administration (TGA), the US Food and Drug Administration (FDA), and Health Canada for its prostate cancer imaging agent Illuccix. It is working to get Illuccix approved for sale in the UK and Europe.
The company also has more than 20 clinical trials underway worldwide. Telix's research and development is focused on prostate, renal (kidney), glioblastoma (brain), and hematologic (bone marrow conditioning) cancers, as well as rare diseases. The company is headquartered in Australia with offices in Belgium, Japan, Switzerland, and the United States.
